Kang Hee-Ju, Bae Kyung-Yeol, Kim Sung-Wan, Shin Il-Seon, Hong Young Joon, Ahn Youngkeun, Jeong Myung Ho, Yoon Jin-Sang, Kim Jae-Min
Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea.
Department of Cardiology, Chonnam National University Medical School, Gwangju, Korea.
Clin Psychopharmacol Neurosci. 2017 May 31;15(2):126-131. doi: 10.9758/cpn.2017.15.2.126.
There are no evidence-based practices for treating anxiety in patients with acute coronary syndrome (ACS). Thus, we investigated the effects of escitalopram on anxiety in this population.
We enrolled 217 patients with ACS who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for depressive disorders into a randomized double-blind placebo-controlled study. Patients received either escitalopram or placebo over a 24-week period. Anxiety symptoms were evaluated using the Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A). A HADS-A score >7 was classified as an anxiety disorder. Baseline evaluations included sociodemographic and clinical characteristics, such as depressive symptoms, cardiovascular risk factors, and current cardiac status.
Independent of improvements in depression and without any differences in safety profiles, escitalopram treatment was significantly more efficacious in treating and reducing anxiety than placebo over a 24-week period.
Escitalopram can be recommended as an effective and safe treatment option for anxiety in patients with ACS.
目前尚无基于证据的治疗急性冠状动脉综合征（ACS）患者焦虑症的方法。因此，我们研究了艾司西酞普兰对该人群焦虑症的影响。
我们将217例符合《精神疾病诊断与统计手册》第4版（DSM-IV）抑郁症标准的ACS患者纳入一项随机双盲安慰剂对照研究。患者在24周内接受艾司西酞普兰或安慰剂治疗。使用医院焦虑抑郁量表-焦虑分量表（HADS-A）评估焦虑症状。HADS-A评分>7被归类为焦虑症。基线评估包括社会人口统计学和临床特征，如抑郁症状、心血管危险因素和当前心脏状况。
在24周的时间里，与抑郁症改善情况无关且安全性方面无任何差异，艾司西酞普兰治疗在治疗和减轻焦虑方面比安慰剂显著更有效。
艾司西酞普兰可被推荐为治疗ACS患者焦虑症的有效且安全的治疗选择。
